Daito Pharmaceutical Co., Ltd. Stock: price and insider trades · Japan
ダイト株式会社
1 insider bought €536k of shares over the last 90 days, the latest by Kaname Capital, L.P., filed 13 Oct 2026.
Daito Pharmaceutical Co., Ltd.: what insiders have been doing
This page follows insider dealings at Daito Pharmaceutical Co., Ltd. as filed with EDINET (Japan FSA), a company from the Health Care sector. From 26 October 2025 to 26 October 2026, the disclosure feed for Daito Pharmaceutical Co., Ltd. logged 7 filings by 2 insiders.
Only purchases show up on the open market, 5 purchases in all, filed by 1 insider. No amount is published for 5 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 major shareholder among the declarants.
With 7 filings in twelve months, the company is more active than the median of 3 filings across the 3,205 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 7 purchases and 33 sales.
The last insider purchase was made public on 13 October 2026, 27 days ago. Filings reach the EDINET (Japan FSA) feed a median of 13 days after the trade. This delay matters because a trade only becomes useful information once it is public.
Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -15.7%Entry JP¥1,328 · Close at T+365 JP¥1,120
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Daito Pharmaceutical Co., Ltd. Hold (neutral), based on 1 analysts. Average price target: JP¥1,390.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended May 2026 · cache
- ShareXTKSEDINET:S100Z7H8
- 11,300 sharesShareXTKSEDINET:S100Z7H8:T1Canonical exit: 3 Dec 2026 (T+90)
- 18,400 sharesShareXTKSEDINET:S100Z7H8:T2Canonical exit: 17 Dec 2026 (T+90)
- 9,500 sharesShareXTKSEDINET:S100Z7H8:T3Canonical exit: 23 Dec 2026 (T+90)
- 8,700 sharesShareXTKSEDINET:S100Z7H8:T4Canonical exit: 29 Dec 2026 (T+90)
- 24,700 sharesShareXTKSEDINET:S100Z7H8:T5Canonical exit: 31 Dec 2026 (T+90)
- ShareXTKSEDINET:S100XIZW
- ShareXTKSEDINET:S100WJ75
- ShareXTKSEDINET:S100WI7S
- ShareXTKSEDINET:S100VWCS
- ShareXTKSEDINET:S100TTI6
- ShareXTKSEDINET:S100TD06
- ShareXTKSEDINET:S100TAFQ
- ShareXTKSEDINET:S100T457
- ShareXTKSEDINET:S100SP60
- ShareXTKSEDINET:S100SKFG
- ShareXTKSEDINET:S100SEVF
- ShareXTKSEDINET:S100S4LY
- 100.0% of flowShareXTKSEDINET:S100RDP2
- ShareXTKSEDINET:S100QVLG
- ShareXTKSEDINET:S100OU5P
- ShareXTKSEDINET:S100ONSP
- ShareXTKSEDINET:S100NZMG
- ShareXTKSEDINET:S100NP2V
- ShareXTKSEDINET:S100NOS2
25 of 63 declarations
About Daito Pharmaceutical Co., Ltd.
Daito Co., Ltd. is a company in the health and pharmaceutical sector, listed on the XTKS market. It specializes in the development and marketing of pharmaceutical and healthcare products.
